Live Breaking News & Updates on 2023 Ash Annual Meeting

Stay updated with breaking news from 2023 ash annual meeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Grants Priority Review to sBLA of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

The FDA has granted priority review to the sBLA of epcoritamab for relapsed/refractory follicular lymphoma. ....

Epcoritamab Bysp Epkinly , Follicular Lymphoma , 2023 Ash Annual Meeting , Phase 1 2 Epcore Nhl Trial Nct03625037 , Jan Van De Winkel ,

SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis. ....

United States , Catherinec Coombs , Angelag Fleischmann , Naveen Pemmaraju , Joshuaf Zeidner , International Consensus Classification , School Of Medicine , Division Of Hematology , Department Of Medicine , World Health Organization , University Of California Irvine , Onclive Institutional Perspectives , California Irvine , New England Journal , Chapel Hill , International Consensus , Bcl2 Inhibitors , Btk Inhibitors , Chronic Lymphocytic Leukemia , Acute Myeloid Leukemia , Hematologic Malignancies , Combination Therapy , 2023 Ash Annual Meeting ,

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma. ....

United States , Hans Lee , Department Of Lymphoma Myeloma , American Society Of Hematology , University Of Texas Md Anderson Cancer Center , Myeloma Clinical Research , Regeneron Pharmaceuticals Inc , Multiple Myeloma Clinical Research , Cancer Center , Multiple Myeloma , Phase 1 2 Linker Mm1 Study , 2023 Ash Annual Meeting , The University Of Texas Md Anderson Cancer Center ,

CD19 CAR T Cells Plus Acalabrutinib Shows Early Activity in Relapsed/Refractory MCL

CD19 CAR T cell therapy plus acalabrutinib demonstrated early efficacy in patients with relapsed/refractory mantle cell lymphoma. ....

Cd19 Cart Cells , Antle Cell Lymphoma Mcl , Phase 1 Study Nct04484012 , 2023 Ash Annual Meeting ,

Obinutuzumab Use Decreases Incidence of Steroid-Requiring cGVHD After Transplant

Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant. ....

Dana Farber Cancer Institute , United States , Corey Cutler , Stanford University , National Institute Of Health , Fritz Laboratory , National Institute , B Cell Depletion , Chronic Graft Vs Host Disease , Hematopoietic Stem Cell Transplant , Phase 2 Study Nct02867384 , 2023 Ash Annual Meeting ,